Literature DB >> 6802510

Two-stage skin carcinogenesis in sensitive and resistant mouse strains.

L K Ashman, A W Murray, M G Cook, I Kotlarski.   

Abstract

Strains of laboratory mice vary markedly in their susceptibility to two-stage skin carcinogenesis using 7,12-dimethylbenz[a]anthracene (DMBA) as the initiating carcinogen and croton oil as promoter. This study has been undertaken in order to clarify the basis of the strain differences. LACA mice were used as the susceptible strain and BALB/c mice as the resistant strain. DMBA was a more effective complete carcinogen in LACA mice than in BALB/c mice. However, dose-response studies with respect to DMBA in the two strains in two-stage carcinogenesis suggested that metabolic activation of DMBA to the active carcinogen was not limiting in the resistant strain. The observed strain differences in response to DMBA in one and two stage carcinogenesis may reflect the ability of DMBA to also act as a promoter in the two strains. The possibility that the strains vary in their ability to repair damaged DNA has, however, not been eliminated. Unlike polycyclic aromatic hydrocarbon carcinogens such as DMBA, phorbol ester promoters (the active components in croton oil) do not appear to require metabolic activation. However, they are degraded and inactivated by epidermal and other cells. Experiments in which the dose and frequency of application of croton oil were increased, and the unrelated promoter anthralin was substituted for croton oil, failed to produce any evidence that differences in promoter degradation contributed to the differences in susceptibility between strains.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802510     DOI: 10.1093/carcin/3.1.99

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Mapping of new skin tumor susceptibility loci by a phenotype-driven congenic approach.

Authors:  Kyoko Fujiwara; Yoshinori Inagaki; Masayoshi Soma; Toshinori Ozaki; Hiroki Nagase
Journal:  Oncol Lett       Date:  2018-09-24       Impact factor: 2.967

2.  Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlate with FAK upregulation.

Authors:  Shin Akakura; Rene Bouchard; Wiam Bshara; Carl Morrison; Irwin H Gelman
Journal:  Int J Cancer       Date:  2011-04-01       Impact factor: 7.396

3.  New outbred colony derived from Mus musculus castaneus to identify skin tumor susceptibility loci.

Authors:  Kyoko Fujiwara; Benjamin Wie; Rosemary Elliott; Hiroki Nagase
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

4.  Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice.

Authors:  Jianjun Shen; Erika L Abel; Penny K Riggs; John Repass; Sean C Hensley; Lisa J Schroeder; Angelina Temple; Alexander Chau; S Alex McClellan; Okkyung Rho; Kaoru Kiguchi; Michael D Ward; O John Semmes; Maria D Person; Joe M Angel; John Digiovanni
Journal:  Carcinogenesis       Date:  2012-07-10       Impact factor: 4.944

Review 5.  Chemically induced skin carcinogenesis: Updates in experimental models (Review).

Authors:  Monica Neagu; Constantin Caruntu; Carolina Constantin; Daniel Boda; Sabina Zurac; Demetrios A Spandidos; Aristidis M Tsatsakis
Journal:  Oncol Rep       Date:  2016-03-17       Impact factor: 3.906

6.  CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway.

Authors:  Xu Zhang; Yeye Guo; Ta Xiao; Jie Li; Aiyuan Guo; Li Lei; Chong Jin; Qi Long; Juan Su; Mingzhu Yin; Hong Liu; Chao Chen; Zhe Zhou; Susi Zhu; Juan Tao; Shuo Hu; Xiang Chen; Cong Peng
Journal:  J Exp Clin Cancer Res       Date:  2022-08-13

7.  New chemically induced skin tumour susceptibility loci identified in a mouse backcross between FVB and dominant resistant PWK.

Authors:  Kyoko Fujiwara; Jun Igarashi; Natsumi Irahara; Makoto Kimura; Hiroki Nagase
Journal:  BMC Genet       Date:  2007-06-28       Impact factor: 2.797

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.